{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:34:26Z","timestamp":1787020466940,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>New biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) all showed greater clinical benefits in the treatment of patients with rheumatoid arthritis (RA) with high disease activity, but imposed higher costs than standard treatment. This study evaluated the cost-effectiveness of 11 alternative treatment strategies for RA patients with high disease activity whose treatment with three conventional synthetic DMARDs (csDMARDs) failed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model was constructed using a societal perspective to estimate relevant costs and health outcomes in terms of quality-adjusted life years (QALYs) for a lifetime horizon (100\u00a0years), given a 3% annual discount. Alternative treatment strategies including five bDMARDs, two tsDMARDs, and four bsDMARDs in combination with methotrexate (MTX) were compared with the standard of care (SoC), i.e., cyclosporine and azathioprine. Direct and non-medical care costs were estimated by identifying the resources used, then multiplied by the standard costing menu in the year 2022. Utility and transitional probabilities were collected in three advanced tertiary hospitals. A network meta-analysis was used to estimate the efficacy of each treatment. Lifetime cost, QALYs and an incremental cost-effectiveness ratio were calculated and compared to the cost-effectiveness threshold of 160,000 THB per QALY gained (US $4,634, where 1 USD\u2009=\u200934.53 THB in 2022). Probabilistic and one-way sensitivity analyses were performed to estimate parameter uncertainties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The bDMARDs, tsDMARDs or bsDMARDs combined with MTX provided 0.09 to 0.33 QALYs gained with additional costs of 550,986 to 2,096,744 THB (US $15,957 to $60,722) compared to the SoC. The ICER ranged from 2.3 to 8.1 million THB per QALY (US $65,935 to $234,996) compared to the SoC. None of these combinations was cost-effective in the Thai context. The results were sensitive to the mortality hazard ratio of patients with high disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combinations of MTX with either bDMARDs, tsDMARDs or bsDMARDs were not economically attractive compared to the standard practice. However, they reduced disease activity and improved patient quality of life. The price negotiation process for these treatments must be conducted to ensure their financial value and affordability before they are included in the pharmaceutical reimbursement list.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-023-09595-1","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T07:02:27Z","timestamp":1685516547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity"],"prefix":"10.1186","volume":"23","author":[{"given":"Juthamas","family":"Prawjaeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattara","family":"Leelahavarong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuttakarn","family":"Budtarad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyot","family":"Pilasant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonticha","family":"Chanjam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanruchada","family":"Katchamart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongthorn","family":"Narongroeknawin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasanee","family":"Kitumnuaypong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"9595_CR1","volume-title":"Pharmacotherapy handbook: McGraw-hill","author":"JT Dipiro","year":"2015","unstructured":"Dipiro JT, DiPiro CV, Schwinghammer TL, Wells BG. Pharmacotherapy handbook: McGraw-hill. 2015."},{"key":"9595_CR2","unstructured":"Division of Non-Communicable Diseases, Department of Disease Control of Thailand: Annual report 2015. Nonthaburi: Office of Printing Affairs of Supporting Veterans; 2016."},{"issue":"2","key":"9595_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","volume":"74","author":"J Listing","year":"2015","unstructured":"Listing J, Kekow J, Manger B, Burmester G-R, Pattloch D, Zink A, Strangfeld A. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415\u201321.","journal-title":"Ann Rheum Dis"},{"key":"9595_CR4","first-page":"27","volume":"66","author":"JR Kalden","year":"2002","unstructured":"Kalden JR. Expanding role of biologic agents in rheumatoid arthritis. J Rheumatol Suppl. 2002;66:27\u201337.","journal-title":"J Rheumatol Suppl"},{"key":"9595_CR5","unstructured":"Thai Rheumatism Association: Clinical practice guideline for rheumatoid arthritis diagnosis and treatment. Bangkok: Thai Rheumatism Association; 2014."},{"key":"9595_CR6","volume-title":"Recommendation for biologic and synthetic targeted DMARDs in Rheumatoid arthritis treatment","author":"Thai rheumatism association","year":"2016","unstructured":"Thai rheumatism association. Recommendation for biologic and synthetic targeted DMARDs in Rheumatoid arthritis treatment. Bangkok: Citiprint; 2016."},{"issue":"8","key":"9595_CR7","first-page":"CD010227","volume":"2016","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev. 2016;2016(8):CD010227.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"9595_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/jcpt.12795","volume":"44","author":"M Camean-Castillo","year":"2019","unstructured":"Camean-Castillo M, Gimeno-Ballester V, Rios-Sanchez E, Fenix-Caballero S, V\u00e1zquez-Real M, Alegre-del Rey E. Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. J Clin Pharm Ther. 2019;44(3):384\u201396.","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"9595_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","volume":"33","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679\u2013707.","journal-title":"Clin Ther"},{"key":"9595_CR10","first-page":"S4","volume":"97","author":"U Chaikledkaew","year":"2014","unstructured":"Chaikledkaew U, Kittrongsiri K. Guidelines for health technology assessment in Thailand (second edition)\u2013the development process. J Med Assoc Thai. 2014;97:S4-9.","journal-title":"J Med Assoc Thai"},{"key":"9595_CR11","unstructured":"Bureau of Trade and Economic Indices, Ministry of Commerce: Report for consumer price index of Thailand in 2022: Base year 2019; 2022. Available from: http:\/\/www.indexpr.moc.go.th\/price_present\/TableIndexG_region.asp?table_name=cpig_index_country&province_code=5&type_code=g&check_f=i&year_base=2562&nyear=2565."},{"issue":"6","key":"9595_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1017\/S0266462319000321","volume":"35","author":"P Leelahavarong","year":"2019","unstructured":"Leelahavarong P, Doungthipsirikul S, Kumluang S, Poonchai A, Kittiratchakool N, Chinnacom D, Suchonwanich N, Tantivess S. Health technology assessment in Thailand: institutionalization and contribution to healthcare decision making: review of literature. Int J Technol Assess Health Care. 2019;35(6):467\u201373.","journal-title":"Int J Technol Assess Health Care"},{"issue":"9","key":"9595_CR13","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.21235","volume":"52","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625\u201336.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"9595_CR14","first-page":"579","volume":"20","author":"D Van der Heijde","year":"1993","unstructured":"Van der Heijde D, Van\u2019t Hof M, Van Riel P, Van de Putte L. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20(3):579\u201381.","journal-title":"J Rheumatol"},{"issue":"1","key":"9595_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"M Prevoo","year":"1995","unstructured":"Prevoo M, Van\u2019T Hof MA, Kuper H, Van Leeuwen M, Van De Putte L, Van Riel P. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheuma. 1995;38(1):44\u20138.","journal-title":"Arthritis Rheuma"},{"issue":"6","key":"9595_CR16","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762\u201384.","journal-title":"Arthritis Rheum"},{"key":"9595_CR17","volume-title":"Health technology assessment process guidelines","author":"R Perez","year":"2012","unstructured":"Perez R, Youngkong S, Tantivess S. Health technology assessment process guidelines. Nonthaburi: Health Intervention and Technology Assessment Program (HITAP); 2012."},{"key":"9595_CR18","doi-asserted-by":"crossref","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford Univ. Press; 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"9595_CR19","unstructured":"Riewpaiboon A. Standard cost lists for health economic evaluation in Thailand. J Med Assoc Thai. 2014;97:S127\u201334."},{"key":"9595_CR20","doi-asserted-by":"crossref","unstructured":"Katchamart W, Narongroeknawin P, Chanapai W, Thaweeratthakul P: Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 2019;3(1):34.","DOI":"10.1186\/s41927-019-0080-9"},{"key":"9595_CR21","unstructured":"World Health Organization: Global Health Observatory data repository: Life tables by country (Thailand); 2018. Available from: https:\/\/apps.who.int\/gho\/data\/?theme=main&vid=61640."},{"key":"9595_CR22","unstructured":"Nuttakarn B, Juthamas P, Pattara L, Songyot P, Chonticha C, Pongthorn N, Tasanee K, Wanruchada K: Efficacy and safety of biologic, biosimilars and targeted synthetic DMARDs in moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: a systematic review and network meta-analysis. medRxiv 2023."},{"issue":"4","key":"9595_CR23","first-page":"951","volume":"15","author":"IR White","year":"2015","unstructured":"White IR: Network meta-analysis. The Stata Journal. 2015;15(4):951\u201385.","journal-title":"Stand Genomic Sci"},{"key":"9595_CR24","unstructured":"Drug and Medical Supply Information Center (DMSIC), Ministry of Public Health: Reference price database; 2021. Available from: http:\/\/dmsic.moph.go.th\/index\/drugsearch\/3."},{"issue":"6","key":"9595_CR25","first-page":"59","volume":"91","author":"S Limwattananon","year":"2011","unstructured":"Limwattananon S. Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thai. 2011;91(6):59.","journal-title":"J Med Assoc Thai"},{"key":"9595_CR26","unstructured":"Tanvejsilp P, Ngorsuraches S: Setting the scope of health technology assessment and health economic evaluation study. In: Guideline for health technology assessment in Thailand (second edition)\u2014the development process. edn. Edited by Chaikledkaew U, Teerawattananon Y. Nonthaburi: Wacharin PP Printing; 2013:10\u201322."},{"issue":"3","key":"9595_CR27","doi-asserted-by":"publisher","first-page":"e0119683","DOI":"10.1371\/journal.pone.0119683","volume":"10","author":"JT Joensuu","year":"2015","unstructured":"Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordstr\u00f6m D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS ONE. 2015;10(3):e0119683.","journal-title":"PLoS ONE"},{"issue":"7","key":"9595_CR28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/ard.2004.027565","volume":"64","author":"NJ Bansback","year":"2005","unstructured":"Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005;64(7):995\u20131002.","journal-title":"Ann Rheum Dis"},{"key":"9595_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.vhri.2015.10.003","volume":"9","author":"A Hashemi-Meshkini","year":"2016","unstructured":"Hashemi-Meshkini A, Nikfar S, Glaser E, Jamshidi A, Hosseini SA. Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model. Value Health Reg Issues. 2016;9:42\u20138.","journal-title":"Value Health Reg Issues"},{"issue":"6","key":"9595_CR30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/annrheumdis-2011-200274","volume":"71","author":"LG Schipper","year":"2012","unstructured":"Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, van Riel P, Fransen J, van de Laar MA. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012;71(6):845\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"9595_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/rheumatology\/keg107","volume":"42","author":"G Kobelt","year":"2003","unstructured":"Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford). 2003;42(2):326\u201335.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"9595_CR32","doi-asserted-by":"publisher","first-page":"e000993","DOI":"10.1136\/rmdopen-2019-000993","volume":"5","author":"K Chatzidionysiou","year":"2019","unstructured":"Chatzidionysiou K, Sfikakis PP. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. RMD Open. 2019;5(2):e000993.","journal-title":"RMD Open"},{"issue":"1","key":"9595_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"9595_CR34","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, Van Vollenhoven R. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-09595-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T08:20:37Z","timestamp":1702542037000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-09595-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["9595"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-09595-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2651221\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the ethics committee at each participating site: the Siriraj Hospital institutional review board (certificate of Approval (CoA) no. Si 553\/2020), the institutional review board of the Royal Thai Army Medical Department (CoA no. Q029h\/2019) and the Rajavithi Hospital institutional review board (CoA no.129\/2020). All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"561"}}